HRTX Stock - Heron Therapeutics, Inc.
Unlock GoAI Insights for HRTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $144.28M | $127.04M | $107.67M | $86.35M | $88.64M |
| Gross Profit | $105.64M | $61.94M | $52.80M | $40.33M | $52.45M |
| Gross Margin | 73.2% | 48.8% | 49.0% | 46.7% | 59.2% |
| Operating Income | $-11,528,000 | $-110,615,000 | $-174,658,000 | $-217,828,000 | $-228,163,000 |
| Net Income | $-13,580,000 | $-110,559,000 | $-182,024,000 | $-220,683,000 | $-227,278,000 |
| Net Margin | -9.4% | -87.0% | -169.1% | -255.6% | -256.4% |
| EPS | $-0.09 | $-0.80 | $-1.67 | $-2.24 | $-2.50 |
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 9th 2025 | H.C. Wainwright | Initiation | Buy | $6 |
| June 13th 2024 | Rodman & Renshaw | Initiation | Buy | $7 |
| April 23rd 2024 | CapitalOne | Initiation | Overweight | $6 |
| March 13th 2024 | Needham | Reiterated | Buy | $5← $4 |
Earnings History & Surprises
HRTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.03 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.01 | $-0.05 | -275.1% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $-0.01 | $-0.02 | -100.0% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.01 | $0.01 | +200.0% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.03 | $0.02 | +166.7% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.03 | $-0.03 | -9.1% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.04 | $-0.06 | -50.0% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.08 | $-0.02 | +75.0% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-0.15 | $-0.07 | +53.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.31 | $-0.17 | +45.2% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.23 | $-0.35 | -52.2% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.17 | $-0.27 | -58.8% | ✗ MISS |
Q1 2023 | Mar 23, 2023 | $-0.25 | $-0.17 | +32.0% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.39 | $-0.38 | +2.6% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.50 | $-0.55 | -10.0% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.45 | $-0.63 | -40.0% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.59 | $-0.54 | +8.5% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.60 | $-0.51 | +15.0% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.59 | $-0.62 | -5.1% | ✗ MISS |
Latest News
Heron Therapeutics Includes APONVIE Injectable Emulsion In Guidelines For Postoperative Nausea, Vomiting
📈 PositiveUPDATE: Heron Therapeutics Q3 Adj. EPS $(0.04) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate
📉 NegativeHeron Therapeutics Affirms FY2025 Sales Guidance of $153.000M-$163.000M vs $156.482M Est
📈 PositiveHeron Therapeutics Q3 EPS $(0.10) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate
📉 NegativeHeron Therapeutics Files For Mixed Shelf Of Up To $125M
➖ NeutralFrequently Asked Questions about HRTX
What is HRTX's current stock price?
What is the analyst price target for HRTX?
What sector is Heron Therapeutics, Inc. in?
What is HRTX's market cap?
Does HRTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HRTX for comparison